Hereditary Aplastic Anemia in Children A Comprehensive Review of Inherited Bone Marrow Failure Syndromes
1. Maryam Ashfaq
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Hereditary aplastic anemia encompasses a heterogeneous group of inherited bone marrow failure syndromes (IBMFS) characterized by impaired hematopoiesis, congenital anomalies, and predisposition to hematologic malignancies and solid tumors. Unlike acquired aplastic anemia, which results from immune-mediated destruction of hematopoietic stem cells, these genetic disorders arise from germline mutations affecting DNA repair, telomere maintenance, ribosome biogenesis, and hematopoietic stem cell regulation. This review examines the current understanding of hereditary aplastic anemias in children, with particular emphasis on Fanconi anemia, Diamond-Blackfan anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, GATA2 deficiency, and SAMD9/SAMD9L syndromes. A comprehensive literature search was conducted focusing on publications from 2017 to 2025, incorporating recent advances in genomic diagnostics, hematopoietic stem cell transplantation protocols, and emerging gene therapy approaches. The analysis reveals that while allogeneic hematopoietic stem cell transplantation remains the only curative therapy for most IBMFS, significant progress has been achieved in reducing transplant-related mortality through reduced-intensity conditioning regimens and improved donor selection. Notably, lentiviral-mediated gene therapy has recently demonstrated sustained efficacy in Fanconi anemia without cytotoxic conditioning, representing a paradigm shift toward non-genotoxic curative approaches. Early genetic diagnosis, comprehensive multidisciplinary surveillance, and individualized treatment strategies are essential for optimizing outcomes in these complex disorders.
Introduction
The bone marrow serves as the cradle of hematopoiesis, generating the erythrocytes, leukocytes, and platelets essential for oxygen transport, immune defense, and hemostasis. When this vital function fails, the consequences are profound and often life-threatening. Aplastic anemia, characterized by pancytopenia and hypocellular bone marrow, has traditionally been classified as acquired or inherited. While acquired aplastic anemia predominates in adult populations and frequently responds to immunosuppressive therapy, hereditary forms of bone marrow failure present distinct diagnostic and therapeutic challenges that demand specialized approaches.
Hereditary aplastic anemia, more accurately termed inherited bone marrow failure syndromes, represents a collection of genetic disorders unified by their impact on hematopoietic stem and progenitor cells. These conditions, though individually rare, collectively account for a significant proportion of childhood bone marrow failure cases and carry substantial morbidity and mortality. The genetic landscape of these disorders has expanded dramatically in recent decades, with more than thirty genes now implicated in various IBMFS. This genetic heterogeneity translates to remarkable phenotypic diversity, ranging from isolated anemia with subtle physical findings to severe pancytopenia accompanied by multi-system congenital anomalies.
The recognition of hereditary aplastic anemia in children carries profound implications beyond the immediate hematologic manifestations. These disorders predispose affected individuals to myelodysplastic syndrome, acute myeloid leukemia, and solid tumors, necessitating lifelong surveillance. Furthermore, the genetic nature of these conditions affects family planning decisions, sibling donor selection for transplantation, and screening of at-risk relatives. The distinction between acquired and inherited forms is therefore not merely academic but fundamentally shapes clinical management.
Fanconi anemia, the most prevalent IBMFS, exemplifies the complexity of these disorders. Caused by mutations in genes involved in DNA interstrand crosslink repair, Fanconi anemia presents with variable congenital anomalies, progressive bone marrow failure, and a markedly elevated cancer risk. The recent success of gene therapy in Fanconi anemia, demonstrating sustained engraftment of genetically corrected hematopoietic stem cells without conditioning chemotherapy, represents a watershed moment in the field. Similarly, Diamond-Blackfan anemia, arising from ribosomal protein gene mutations, illustrates how defects in fundamental cellular processes manifest as tissue-specific failure of erythropoiesis.
This review aims to provide a comprehensive examination of hereditary aplastic anemia in children, encompassing the major IBMFS with emphasis on recent advances in diagnosis, treatment, and long-term management. The evolving role of gene therapy, refinements in hematopoietic stem cell transplantation, and emerging targeted therapies are explored in detail.
Methods
A comprehensive literature search was conducted to identify relevant publications addressing hereditary aplastic anemias and inherited bone marrow failure syndromes in pediatric populations. The search encompassed databases including PubMed, MEDLINE, and the Cochrane Library, with primary focus on literature published between January 2017 and October 2025 to ensure inclusion of contemporary management guidelines and emerging therapeutic data. Search terms incorporated "inherited bone marrow failure syndrome," "Fanconi anemia," "Diamond-Blackfan anemia," "dyskeratosis congenita," "Shwachman-Diamond syndrome," "GATA2 deficiency," "SAMD9," "pediatric," "children," "gene therapy," and "hematopoietic stem cell transplantation."
Inclusion criteria prioritized original research articles, systematic reviews, clinical practice guidelines, and results from clinical trials specifically addressing pediatric populations or containing substantial pediatric subgroups. The methodological framework emphasized evidence-based guidelines from hematological societies including the Fanconi Anemia Research Fund Clinical Care Guidelines, the Diamond-Blackfan Anemia Registry data, and recent international consensus statements. Particular attention was directed toward studies characterizing treatment outcomes, novel therapeutic agents including gene therapy approaches, and long-term follow-up data in pediatric cohorts.
The analysis synthesized data from multiple study designs, acknowledging the inherent limitations of rare disease research where randomized controlled trials are scarce and therapeutic recommendations frequently derive from retrospective cohort studies, disease registries, and expert consensus. Reference was made to key epidemiological studies, including recent single-center retrospective analyses, multinational registry data, and the landmark FANCOLEN-1 gene therapy trial published in The Lancet.
Results
Epidemiology and Classification
Inherited bone marrow failure syndromes, while individually rare, collectively represent a significant cause of pediatric hematologic disease. The cumulative prevalence is estimated at approximately 65 per million live births, though under-diagnosis remains likely given the variable phenotypic expression and recent recognition of novel genetic etiologies. Fanconi anemia and Diamond-Blackfan anemia are believed to be the most prevalent IBMFS, each occurring at approximately 1 in 150,000 births, though precise epidemiological data remain limited by ascertainment bias and evolving diagnostic criteria.
The classification of hereditary aplastic anemias has traditionally been organized by the predominant hematologic lineage affected and the underlying molecular pathophysiology. Fanconi anemia, caused by defects in the FA/BRCA DNA repair pathway, typically presents with progressive pancytopenia and characteristic congenital anomalies including radial ray defects, café-au-lait spots, and short stature. Diamond-Blackfan anemia, arising from heterozygous mutations in ribosomal protein genes in approximately 75% of cases, manifests as isolated macrocytic anemia with reticulocytopenia and reduced erythroid precursors in an otherwise normocellular bone marrow. Dyskeratosis congenita and related telomere biology disorders result from defective telomere maintenance and present with the mucocutaneous triad of dystrophic nails, abnormal skin pigmentation, and oral leukoplakia, though these features may be absent in young children. Shwachman-Diamond syndrome, caused by mutations in the SBDS gene, combines bone marrow failure with exocrine pancreatic insufficiency and skeletal abnormalities. More recently recognized entities include GATA2 deficiency, characterized by monocytopenia, mycobacterial infections, and myelodysplastic syndrome predisposition, and SAMD9/SAMD9L syndromes, which demonstrate remarkable phenotypic variability from severe MIRAGE syndrome to milder ataxia-pancytopenia presentations.
Molecular Pathophysiology
The molecular mechanisms underlying hereditary aplastic anemias illuminate fundamental biological processes while explaining the clinical heterogeneity observed. Fanconi anemia arises from biallelic mutations in one of at least 22 genes encoding proteins that coordinate repair of DNA interstrand crosslinks. The FA pathway proteins normally function to recognize and repair DNA damage, particularly crosslinks induced by endogenous aldehydes and exogenous agents. When this pathway fails, hematopoietic stem cells accumulate genomic damage, triggering cell cycle arrest, apoptosis, and eventual stem cell exhaustion. The hypersensitivity of FA cells to DNA crosslinking agents forms the basis of the diagnostic diepoxybutane and mitomycin C chromosomal breakage tests.
Diamond-Blackfan anemia represents the prototypical ribosomopathy, with heterozygous mutations in ribosomal protein genes including RPS19, RPL5, RPS26, and others accounting for the majority of cases. These mutations impair ribosome biogenesis, triggering nucleolar stress and activation of the tumor suppressor p53. The erythroid lineage demonstrates particular vulnerability to ribosomal insufficiency, though the precise mechanisms remain incompletely understood. Recent evidence suggests that dysregulation of heme synthesis and globin translation, with accumulation of toxic free heme in erythroblasts, contributes to the erythroid-specific failure. The observation that some patients experience spontaneous remission suggests compensatory mechanisms may occasionally restore effective erythropoiesis.
Dyskeratosis congenita and telomere biology disorders result from mutations in genes encoding components of the telomerase complex or telomere-protective proteins, including TERT, TERC, DKC1, TINF2, and others. Progressive telomere shortening leads to replicative senescence and apoptosis of hematopoietic stem cells, explaining the often-delayed onset of bone marrow failure even in children with congenital features. The accelerated biological aging also predisposes to pulmonary fibrosis, liver disease, and malignancy.
Shwachman-Diamond syndrome, caused by biallelic mutations in SBDS, impairs ribosome maturation through defective processing of the 60S ribosomal subunit. The protein participates in the release of eukaryotic initiation factor 6 from the 60S subunit, a critical step in ribosome assembly. The combination of hematologic and pancreatic manifestations reflects the tissue-specific requirements for high translational capacity.
GATA2 deficiency arises from heterozygous mutations in the hematopoietic transcription factor GATA2, which is essential for stem cell survival and differentiation. The disorder demonstrates age-related penetrance, with hematologic manifestations often emerging in adolescence or young adulthood, though pediatric presentations occur. SAMD9 and SAMD9L, located on chromosome 7, function as interferon-inducible inhibitors of cellular proliferation. Gain-of-function mutations cause growth restriction and bone marrow failure through excessive anti-proliferative signaling, with somatic genetic rescue through acquisition of monosomy 7 or secondary mutations representing a characteristic disease-modifying mechanism.
Clinical Presentation
The clinical manifestations of hereditary aplastic anemia in children vary enormously, reflecting the underlying genetic heterogeneity and the specific hematopoietic lineages affected. Fanconi anemia typically presents between birth and age ten to fifteen years, though diagnosis in adulthood increasingly recognized. Approximately 75% of affected children exhibit one or more congenital anomalies, including café-au-lait spots, short stature, thumb and radial abnormalities, microcephaly, microphthalmia, renal structural anomalies, and cardiac defects. However, the absence of physical abnormalities does not exclude the diagnosis, as some patients present solely with hematologic manifestations. The bone marrow failure typically evolves gradually, with thrombocytopenia and anemia often preceding neutropenia. Notably, myelodysplastic syndrome or acute myeloid leukemia may occasionally herald the diagnosis in children without prior recognized hematologic abnormalities.
Diamond-Blackfan anemia presents in infancy or early childhood, with 90% of cases diagnosed before the first birthday. The anemia is characteristically macrocytic with reticulocytopenia, while leukocyte and platelet counts remain normal or only mildly reduced. Approximately 50% of patients have congenital anomalies, including craniofacial abnormalities such as hypertelorism and flat nasal bridge, thumb malformations, short stature, and cardiac defects. The growth retardation may be disproportionate to the degree of anemia, suggesting intrinsic growth plate abnormalities. Some patients exhibit elevated erythrocyte adenosine deaminase activity, a useful diagnostic adjunct though not universally present.
Dyskeratosis congenita in young children may lack the classic mucocutaneous features that develop with age. Bone marrow failure, when present, typically emerges later than in Fanconi anemia, often in the second decade, though severe early-onset forms occur. Families with autosomal dominant inheritance may demonstrate anticipation, with progressively earlier and more severe manifestations in successive generations due to inheritance of progressively shortened telomeres.
Shwachman-Diamond syndrome presents in infancy with steatorrhea, failure to thrive, and recurrent infections due to neutropenia. The neutropenia is often intermittent initially but becomes persistent and severe in most patients. Progressive bone marrow failure affecting all lineages develops in a substantial proportion, with approximately one-third of patients developing clonal cytogenetic abnormalities, particularly isochromosome 7q, which confers high risk of myelodysplastic syndrome and acute myeloid leukemia.
GATA2 deficiency may present with warts, nontuberculous mycobacterial infections, pulmonary alveolar proteinosis, or sensorineural hearing loss before overt bone marrow failure becomes apparent. The combination of monocytopenia and B-cell lymphopenia with elevated CD4/CD8 ratio provides diagnostic clues. SAMD9/SAMD9L syndromes demonstrate extreme phenotypic variability, from the severe MIRAGE syndrome presenting at birth with growth restriction, adrenal hypoplasia, and genital anomalies, to milder forms with isolated hematologic abnormalities and neurological features.
Diagnostic Evaluation
The diagnostic approach to suspected hereditary aplastic anemia requires integration of clinical assessment, laboratory evaluation, and genetic testing. Initial laboratory studies include complete blood count with reticulocyte count, which typically demonstrates pancytopenia with inadequate reticulocyte response. Macrocytosis, when present, suggests Diamond-Blackfan anemia or a telomere biology disorder. Elevated fetal hemoglobin and erythrocyte adenosine deaminase activity support Diamond-Blackfan anemia, though these findings are neither sensitive nor specific.
Bone marrow examination is essential for evaluating cellularity and excluding malignancy. Fanconi anemia typically demonstrates progressive hypocellularity with relative preservation of lymphocytes and plasma cells. Diamond-Blackfan anemia characteristically shows normocellular marrow with markedly reduced or absent erythroid precursors. Cytogenetic analysis of bone marrow is critical for identifying clonal abnormalities including monosomy 7, isochromosome 7q, or complex karyotypes that may indicate evolution to myelodysplastic syndrome.
The chromosomal breakage test using diepoxybutane or mitomycin C remains the gold standard for Fanconi anemia diagnosis, demonstrating increased chromosomal breakage and radial formation in FA cells compared to controls. However, somatic mosaicism, occurring in a substantial proportion of FA patients due to genetic reversion in hematopoietic stem cells, can yield false-negative results, necessitating testing of skin fibroblasts when clinical suspicion persists. Telomere length measurement by flow cytometry with fluorescence in situ hybridization on peripheral blood lymphocytes identifies patients with telomere biology disorders, with age-adjusted values below the first percentile considered diagnostic.
Genetic testing has revolutionized the diagnosis of hereditary aplastic anemias. Next-generation sequencing panels encompassing IBMFS-associated genes enable rapid, cost-effective molecular diagnosis. Whole exome sequencing is increasingly employed for patients with negative panel testing, with functional validation of variants of uncertain significance through splicing assays, complementation studies, or protein expression analysis. For SAMD9/SAMD9L syndromes, testing of non-hematopoietic tissue is recommended when monosomy 7 is present, as the chromosome 7 deletion may remove the mutant allele and mask the germline mutation.
Treatment Approaches
Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation remains the only curative therapy for the hematologic manifestations of most hereditary aplastic anemias. The evolution of transplantation protocols has dramatically improved outcomes, with fludarabine-based reduced-intensity conditioning regimens now standard for Fanconi anemia, substantially reducing regimen-related toxicity while maintaining engraftment. The use of alternative donors, including matched unrelated donors, umbilical cord blood, and haploidentical family donors, has expanded access to transplantation, though outcomes remain superior with matched sibling donors.
For Fanconi anemia, transplantation is ideally performed before the onset of severe bone marrow failure or clonal evolution, with optimal outcomes in younger patients without significant organ dysfunction. The conditioning regimen must balance effective immunosuppression and stem cell ablation against the extreme sensitivity of FA patients to DNA-damaging agents. Fludarabine-based protocols with reduced doses of cyclophosphamide and radiation have achieved survival rates exceeding 80% in favorable-risk patients, though outcomes are poorer for those with advanced myelodysplastic syndrome or acute myeloid leukemia.
Diamond-Blackfan anemia presents distinct transplantation considerations. Matched sibling donor transplantation is recommended for transfusion-dependent patients, particularly those under ten years of age, with excellent outcomes reported. However, alternative donor transplantation has historically been associated with poorer outcomes, though recent improvements in conditioning regimens and graft-versus-host disease prophylaxis are narrowing this gap. The decision to transplant must weigh the risks of procedure-related mortality against the long-term complications of chronic transfusion and iron overload.
For dyskeratosis congenita, reduced-intensity conditioning is essential given the extreme sensitivity to organ toxicity, particularly pulmonary and hepatic. The use of fludarabine with low-dose cyclophosphamide or melphalan, often with T-cell depletion to reduce graft-versus-host disease, has improved outcomes. However, long-term survivors remain at risk for pulmonary fibrosis and other non-hematologic manifestations of the underlying telomere defect.
Shwachman-Diamond syndrome patients with severe bone marrow failure or clonal evolution undergo transplantation with reduced-intensity conditioning, though outcomes for those with established myelodysplastic syndrome remain suboptimal due to therapy-resistant disease and treatment toxicity. GATA2 deficiency requires early transplantation before the development of advanced myelodysplastic syndrome, with recent studies demonstrating that outcomes are comparable to those of patients with myelodysplastic syndrome without GATA2 mutations when transplanted at early disease stages.
Medical Management
For patients without suitable donors or those awaiting transplantation, medical management aims to maintain hematopoietic function and prevent complications. Androgen therapy, particularly with oxymetholone or danazol, stimulates erythropoiesis in approximately 50% of Fanconi anemia patients and a substantial proportion of those with dyskeratosis congenita. However, androgens are ineffective in Diamond-Blackfan anemia and Shwachman-Diamond syndrome. Side effects include virilization, hepatic toxicity, and premature epiphyseal closure, necessitating careful monitoring in growing children.
Hematopoietic growth factors, including granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, are employed in Shwachman-Diamond syndrome for severe neutropenia with recurrent infections, though they do not address the underlying marrow failure and may theoretically stimulate malignant clones. Erythropoietin is generally ineffective in IBMFS, as the primary defect lies in stem cell number and function rather than cytokine signaling.
Red blood cell transfusions form the mainstay of management for Diamond-Blackfan anemia patients who are steroid-refractory or cannot be weaned to acceptable steroid doses. Transfusion-dependent patients require iron chelation to prevent transfusion-related iron overload, with deferasirox or deferoxamine initiated when ferritin exceeds 500 ng/mL or transferrin saturation exceeds 60%. Early initiation of chelation and regular monitoring of liver iron content by magnetic resonance imaging are essential for preventing hepatic, cardiac, and endocrine complications.
Corticosteroids remain the primary therapy for Diamond-Blackfan anemia, with approximately 80% of patients demonstrating initial response. The typical starting dose of prednisone is 2 mg/kg/day, with response assessed by reticulocyte rise and hemoglobin stabilization within two to four weeks. Patients are gradually tapered to the lowest effective maintenance dose, ideally not exceeding 0.3 mg/kg/day or 0.6 mg/kg every other day. However, significant steroid toxicity including growth retardation, pathologic fractures, and cataracts has led to increasingly conservative approaches, with many experts now favoring transfusion over high-dose steroids in infants to avoid compromising growth and development.
Emerging Therapies
The therapeutic landscape for hereditary aplastic anemias is being transformed by gene therapy and targeted molecular approaches. The recent publication of the FANCOLEN-1 trial results in The Lancet represents a landmark achievement, demonstrating for the first time that lentiviral-mediated gene therapy without cytotoxic conditioning can achieve sustained engraftment and reversal of bone marrow failure in Fanconi anemia patients. In this trial, autologous CD34+ cells were transduced with a therapeutic FANCA-encoding lentiviral vector and reinfused without conditioning chemotherapy. The primary endpoint was met in five of eight evaluable patients, with progressive increases in genetically corrected cells observed over time, reflecting the survival advantage of corrected hematopoietic stem cells. No genotoxic events related to gene therapy were observed, and most adverse events were non-serious childhood illnesses.
The success of FANCOLEN-1 builds upon decades of iterative improvements in vector design, transduction protocols, and stem cell mobilization. The use of granulocyte colony-stimulating factor combined with plerixafor enables collection of adequate CD34+ cells even from patients with early bone marrow failure, while shortened ex vivo culture and addition of cytoprotective agents improve viability of fragile FA cells. These advances have enabled treatment of children as young as one year of age, potentially before severe marrow failure develops.
For Diamond-Blackfan anemia, gene therapy approaches utilizing lentiviral vectors to deliver functional ribosomal protein genes are in preclinical development, with proof-of-concept studies in murine models demonstrating correction of anemia and prevention of fatal bone marrow failure. The challenge of achieving high-level transduction of hematopoietic stem cells while avoiding insertional mutagenesis remains, though newer vector designs with self-inactivating long terminal repeats and tissue-specific promoters enhance safety. CRISPR/Cas9-mediated correction of pathogenic variants, potentially combined with non-integrating lentiviral delivery of editing machinery, represents a future direction.
Novel pharmacological approaches are also emerging. Eltrombopag, a thrombopoietin receptor agonist, is under investigation in Fanconi anemia based on preclinical evidence that it not only stimulates megakaryopoiesis but also improves DNA double-strand break repair, a fundamental defect in FA. Metformin, which activates AMP-activated protein kinase and may reduce oxidative stress, demonstrated short-term safety and potential efficacy in a small clinical trial of FA patients with cytopenias. For Diamond-Blackfan anemia, L-leucine supplementation has shown promise in preclinical models and early clinical experience, potentially acting through mTORC1 pathway activation to enhance protein synthesis in ribosome-deficient cells.
The development of antibody-based conditioning agents, such as anti-CD117 (briquilimab) and anti-CD45, offers the potential to achieve stem cell depletion without the genotoxic effects of chemotherapy or radiation. These approaches are particularly attractive for DNA repair-deficient disorders like Fanconi anemia, where conventional conditioning carries high risks of secondary malignancy and organ toxicity. Preclinical studies and early phase clinical trials are evaluating these agents in combination with reduced-intensity or non-genotoxic regimens.
Surveillance and Long-term Management
The management of hereditary aplastic anemia extends far beyond the immediate treatment of cytopenias. These disorders carry substantial risks of malignant transformation, necessitating lifelong surveillance. Fanconi anemia patients require regular monitoring for head and neck squamous cell carcinoma, gynecologic malignancies, and esophageal cancer, with surveillance typically commencing in the second decade. The risk of myelodysplastic syndrome and acute myeloid leukemia necessitates regular bone marrow examinations with cytogenetic analysis, with the frequency individualized based on the specific disorder, genotype, and clinical stability.
Iron overload monitoring is essential for all transfusion-dependent patients, with annual assessment of liver iron concentration by MRI and regular evaluation of cardiac function. Endocrine surveillance includes monitoring for growth hormone deficiency, hypothyroidism, hypogonadism, and diabetes mellitus, which may result from iron deposition or direct effects of the underlying genetic disorder.
The psychosocial impact of these chronic conditions on children and families requires attention. The burden of regular medical appointments, treatment-related restrictions, and uncertainty regarding long-term outcomes affects quality of life. Multidisciplinary care teams including hematologists, endocrinologists, gastroenterologists, genetic counselors, psychologists, and social workers provide comprehensive support. Genetic counseling is essential for affected families, addressing recurrence risks, options for prenatal diagnosis, and implications for sibling donor selection.
Prognosis and Outcomes
The prognosis for children with hereditary aplastic anemia has improved dramatically with advances in transplantation and supportive care. For Fanconi anemia, overall survival following matched sibling donor transplantation now exceeds 80% in patients without advanced disease, with many survivors achieving normal hematopoietic function and quality of life. However, the risk of secondary malignancies, particularly head and neck cancers, persists even after successful transplantation, reflecting the underlying cancer predisposition.
Diamond-Blackfan anemia demonstrates variable natural history, with some patients achieving spontaneous remission while others remain transfusion-dependent or steroid-responsive throughout life. The overall survival at forty years exceeds 75%, with corticosteroid-responsive patients demonstrating superior outcomes compared to transfusion-dependent patients. However, a substantial proportion of deaths are treatment-related, emphasizing the need for optimized therapeutic strategies.
The outlook for patients with dyskeratosis congenita has improved with reduced-intensity transplantation, though long-term complications including pulmonary fibrosis and liver disease continue to limit survival. Shwachman-Diamond syndrome patients face ongoing risks of myelodysplastic syndrome and acute myeloid leukemia even after transplantation, with particularly poor outcomes for those who develop therapy-resistant disease.
Discussion
The field of hereditary aplastic anemia stands at an inflection point, with the convergence of genomic medicine, improved transplantation techniques, and gene therapy promising to transform outcomes for these challenging disorders. The recent demonstration that gene therapy can achieve sustained hematopoietic correction in Fanconi anemia without genotoxic conditioning represents a paradigm shift, offering hope that curative approaches may soon extend to other IBMFS.
However, significant challenges remain. The genetic heterogeneity of these disorders complicates the development of universally applicable therapies. While gene therapy for Fanconi anemia type A, caused by FANCA mutations accounting for approximately two-thirds of cases, is advancing rapidly, similar approaches for other complementation groups and other IBMFS require separate vector development and validation. The fragility of hematopoietic stem cells in DNA repair disorders complicates ex vivo manipulation, and achieving therapeutic levels of genetically corrected cells without conditioning remains challenging for disorders lacking a strong selective advantage for corrected cells.
The optimal timing of intervention continues to generate debate. Early transplantation or gene therapy, before the onset of severe bone marrow failure or clonal evolution, offers theoretical advantages but exposes young children to procedure-related risks. Conversely, delayed intervention risks progression to myelodysplastic syndrome or acute myeloid leukemia, which carry substantially worse prognoses. The development of biomarkers predictive of disease progression would greatly inform these decisions, potentially identifying patients who would benefit from early aggressive intervention versus those who could be safely observed.
The expanding recognition of IBMFS in adolescents and adults challenges traditional pediatric-focused paradigms. GATA2 deficiency and milder forms of Fanconi anemia and dyskeratosis congenita may present in adolescence or young adulthood, requiring transition of care from pediatric to adult providers with expertise in these rare disorders. The establishment of specialized adult clinics for IBMFS and the development of transition protocols are essential for ensuring continuity of care.
The psychosocial burden of these disorders on affected children and their families deserves greater attention. The uncertainty regarding disease progression, the burden of surveillance, and the impact on fertility, education, and social development require comprehensive support services. Patient registries and advocacy organizations play crucial roles in connecting families, facilitating research, and advocating for improved access to specialized care.
Future research priorities include the development of non-genotoxic conditioning regimens applicable across IBMFS, refinement of gene editing technologies for precise correction of pathogenic variants, and identification of pharmacological approaches that address fundamental disease mechanisms. The integration of multi-omics approaches to identify biomarkers of disease progression and treatment response may enable personalized therapeutic strategies. International collaborative networks are essential for accruing sufficient patients to power clinical trials and generate robust evidence to guide management.
Conclusion
Hereditary aplastic anemia in children encompasses a diverse group of inherited bone marrow failure syndromes unified by genetic defects compromising hematopoietic stem cell function. The recognition of these disorders has profound implications for treatment selection, surveillance strategies, and family counseling. While allogeneic hematopoietic stem cell transplantation remains the standard curative approach, recent advances in reduced-intensity conditioning and alternative donor selection have substantially improved outcomes. The landmark success of gene therapy in Fanconi anemia, demonstrating sustained engraftment of genetically corrected cells without cytotoxic conditioning, heralds a new era of potentially curative, non-genotoxic therapies.
The management of these complex disorders requires multidisciplinary expertise, integrating hematology, genetics, transplantation, and supportive care. Lifelong surveillance for malignant complications remains essential even after successful hematologic correction. As gene therapy and targeted molecular approaches continue to advance, the outlook for children with these historically devastating disorders continues to improve, offering hope for cure without the long-term toxicities of conventional approaches.
References
Rio P, Navarro S, Gálvez E, Sánchez-Domínguez R, Nicoletti E, Sebastián E, et al. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. Lancet. 2025;404(10471):2584-2592.
Deng J, et al. Inherited Bone Marrow Failure Syndromes: A review of the current understanding of diagnosis and treatment. Curr Pediatr Rep. 2022;10(1):1-15.
Janczar S, et al. Established and emerging non-cellular therapies in inherited bone marrow failure syndromes. Front Immunol. 2026;17:1773574.
Fanconi Anemia Clinical Care Guidelines. 4th ed. Fanconi Anemia Research Fund; 2020.
Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116(19):3715-3723.
Bortnick R, Wlodarski M, de Haas V, et al. Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplant. 2021;56(11):2732-2741.
Khincha PP, Wentzensen IM, Giri N, et al. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165(3):349-357.
Ebens CL, MacMillan ML, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol. 2017;10(1):81-97.
Czechowicz A, Sevilla J, Booth C, et al. Lentiviral-mediated gene therapy for patients with Fanconi anemia [Group A]: Updated results from global RP-L102 clinical trials. Blood. 2024;144(Supplement 1):7463.
Pollard JA, Furutani E, Liu S, et al. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Adv. 2022;6(12):3803-3811.
Fiesco-Roa MO, Giri N, McReynolds LJ, et al. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood Rev. 2019;37:100589.
Sakaguchi H, Yoshida N. Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes. Int J Hematol. 2022;116(1):16-27.
Hofmann I, Avagyan S, Stetson A, et al. Comparison of outcomes of myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations. Biol Blood Marrow Transplant. 2020;26(6):1124-1130.
Bhoopalan SV, Wlodarski M, Reiss U, et al. Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review. Pediatr Blood Cancer. 2021;68(10):e29177.
Thompson AS, Saba N, McReynolds LJ, et al. The causes of Fanconi anemia in South Asia and the Middle East: A case series and review of the literature. Mol Genet Genomic Med. 2021;9(7):e1693.